The decision on the EUA application of the Janssen COVID-19 vaccine can be made next week, according to Domingo.
Food and Drug Administration (FDA) Director-General Eric Domingo hoped that a decision on the emergency use authorization (EUA) application of Johnson & Johnson’s pharmaceutical arm Janssen for its COVID-19 vaccine can be made next week amidst reports of blood clotting among those who had received the said vaccine in the United States.
Domingo said in an interview with INQUIRER.net’s INQside Look that the national government’s vaccine expert panel (VEP) was already scheduled to submit their recommendation on the said vaccine on Wednesday.
However, the recommendation was delayed following reports on the effects of the Janssen COVID-19 vaccines — including blood clots — in the United States.
Domingo also shared that what the VEP did was that they got more data on the said phenomenon that was being observed in the United States and was going to be included in their deliberations instead of giving the reports immediately.
READ ALSO: FDA Confirms Janssen Submits Application For Emergency Use Of COVID-19 Vaccines In PH
When asked for a timeline on the FDA decision on the EUA application, Domingo said that he wanted it to be done “by next week”.
“For these applications from companies that already have an EUA from a stringent regulatory authority like US, EU [European Union], at WHO [World Health Organization], alam kasi naman natin, kumpleto naman na ‘yung requirements diyan. I think they applied March 31, so they are on their 14th or 15th day, I want it to be done by next week,” Domingo said.
What can you say about this? Let us know in the comments below.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.